Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market index [3][5]. Core Insights - The company has demonstrated steady revenue growth, achieving an operating income of 4.013 billion yuan in 2023, a year-on-year increase of 24.12%, and a net profit attributable to shareholders of 666 million yuan, up 29.60% from the previous year [2][5]. - The growth trajectory continued into the first quarter of 2024, with operating income reaching 978 million yuan, reflecting a 5.09% year-on-year increase, and a net profit of 156 million yuan, up 3.75% [2]. - All business segments are experiencing growth, with the cataract business showing the most significant increase, generating 987 million yuan in revenue, a 31.38% year-on-year growth [2]. - The company's overall gross margin slightly improved to 49.03% in 2023, with the cataract and posterior segment projects seeing increases in gross margin of 5.68% and 3.60%, respectively [2]. - The strategic focus on "internal growth + external mergers and acquisitions" is evident, with the company expanding its network of optical centers to 60 by the end of 2023, and plans to acquire 200 centers in the coming years [2][3]. Financial Projections - The company forecasts operating revenues of 4.732 billion yuan, 5.674 billion yuan, and 6.876 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 707 million yuan, 867 million yuan, and 1.153 billion yuan [5][6]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.84 yuan, 1.03 yuan, and 1.37 yuan, respectively, with price-to-earnings (P/E) ratios of 28.00, 22.85, and 17.17 [5][6].
华厦眼科：2023年报、2024年一季报点评：业绩增长态势延续，扩张战略稳步推进